Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo‐controlled study in polycystic ovary syndrome
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Summary: Objective Recent studies suggested that the effect of adiponectin on insulin‐stimulated glucose metabolism is mediated primarily by the high molecular weight (HMW) form of adiponectin. In the present study we evaluated total and HMW adiponectin in polycystic ovary syndrome (PCOS) patients and controls and examined possible mechanisms for increased insulin sensitivity during pioglitazone treatment. Study subjects Thirty PCOS patients randomized to pioglitazone, 30 mg/day, or placebo for 16 weeks and 14 weight‐matched healthy females were studied. Design Total and HMW adiponectin levels were measured, and euglycaemic hyperinsulinaemic clamps and indirect calorimetry were performed. Δ‐values denoted changes during pioglitazone treatment (16 weeks – basal). Results Pretreatment adiponectin levels were decreased in PCOS patients vs. controls (P < 0·05), whereas no significant differences were found in HMW adiponectin levels. Following pioglitazone treatment, total and HMW adiponectin increased (all P < 0·05), whereas no significant changes were observed with placebo. Δ‐total adiponectin levels correlated positively with the rate of Δ‐insulin‐stimulated glucose disposal (Rd) (r = 0·89) and Δ‐oxidative glucose metabolism (r = 0·71) and inversely with Δ‐fasting free fatty acid (FFA) levels (r = –0·69) and Δ‐lipid oxidation (r = –0·73) during insulin stimulation (all P < 0·01). Weaker correlations were found between Δ‐HMW adiponectin levels and Δ‐measures of glucose and lipid metabolism during insulin stimulation than with Δ‐total adiponectin. Conclusion A close correlation between increased total adiponectin levels and increased insulin‐stimulated glucose metabolism during pioglitzone treatment supports the hypothesis that the insulin‐sensitizing effect of pioglitazone in PCOS is, at least in part, mediated by adiponectin. Measures of changes in HMW adiponectin did not add further information to this relationship.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257
Pajvani, U. B., Hawkins, M., Combs, T. P., Rajala, M. W., Doebber, T., Berger, J. P., Wagner, J. A., Wu, M., Knopps, A., Xiang, A. H., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311113200 · Cited by 1,163
Metformin in polycystic ovary syndrome: systematic review and meta-analysis
Lord, J. M., Flight, I. H. K., & Norman, R. J. (2003) · BMJ · doi:10.1136/bmj.327.7421.951 · Cited by 786
Miyazaki, Y., Mahankali, A., Matsuda, M., Mahankali, S., Hardies, J., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.6.8567 · Cited by 726
Mayerson, A. B., Hundal, R. S., Dufour, S., Lebon, V., Befroy, D., Cline, G. W., Enocksson, S., Inzucchi, S. E., Shulman, G. I., & Petersen, K. F. (2002) · Diabetes · doi:10.2337/diabetes.51.3.797 · Cited by 647
Dunaif, A., Xia, J., Book, C. B., Schenker, E., & Tang, Z. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118126 · Cited by 561
Corbould, A., Kim, Y.-B., Youngren, J. F., Pender, C., Kahn, B. B., Lee, A., & Dunaif, A. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00361.2004 · Cited by 283
Cited by
Tang, T., Lord, J. M., Norman, R. J., Yasmin, E., & Balen, A. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003053.pub5 · Cited by 698
Yau, S. Y., Li, A., Hoo, R. L. C., Ching, Y. P., Christie, B. R., Lee, T. M. C., Xu, A., & So, K.-F. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415219111 · Cited by 326
“Given that the major forms of adiponectin in the CNS are trimeric and hexameric, and that the distribution of ADNR1 is mostly detected at the moodregulatory regions (e.g., medial prefrontal cortex, hippocampus and amygdala) (20), ADNR1 seemed to be the possible candidate for mediating the antidepressant effects of phy…”
BackgroundInfluentialAdiponectin action from head to toe
Brochu-Gaudreau, K., Rehfeldt, C., Blouin, R., Bordignon, V., Murphy, B. D., & Palin, M.-F. (2010) · Endocrine · doi:10.1007/s12020-009-9278-8 · Cited by 322
Morley, L. C., Tang, T., Yasmin, E., Norman, R. J., & Balen, A. H. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003053.pub6 · Cited by 296
Adiponectin receptor signalling in the brain
Thundyil, J., Pavlovski, D., Sobey, C. G., & Arumugam, T. V. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01560.x · Cited by 280
Metadata
- Authors
- Glintborg, D., Frystyk, J., Højlund, K., Andersen, K. K., Henriksen, J. E., Hermann, A. P., Hagen, C., Flyvbjerg, A., & Andersen, M.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2007-07-26
- Volume
- 68
- Issue
- 2
- Pages
- 165-174
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2046933321
- Cited by
- 69
- References
- 7
- FWCI
- 9.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo‐controlled study in polycystic ovary syndrome. https://app.cochat.ai/papers/10.1111/j.1365-2265.2007.03015.x
- The paper
- Glintborg, D., Frystyk, J., Højlund, K., Andersen, K. K., Henriksen, J. E., Hermann, A. P., Hagen, C., Flyvbjerg, A., & Andersen, M. (2008). Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo‐controlled study in polycystic ovary syndrome. Clinical Endocrinology. https://doi.org/10.1111/j.1365-2265.2007.03015.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.